Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2. [electronic resource]
Producer: 20200618Description: 1184-1187 p. digitalISSN:- 1468-330X
- Adult
- Antineoplastic Agents -- metabolism
- Blotting, Western
- Caspase 3 -- drug effects
- Cyclin D1 -- drug effects
- Humans
- Immunohistochemistry
- Leukocytes, Mononuclear -- drug effects
- Mitogen-Activated Protein Kinase 1 -- drug effects
- Mitogen-Activated Protein Kinase 3 -- drug effects
- Molecular Targeted Therapy
- Neurofibromatosis 2 -- drug therapy
- Proto-Oncogene Proteins c-akt -- drug effects
- Receptor, Platelet-Derived Growth Factor beta -- drug effects
- Ribosomal Protein S6 -- drug effects
- Sorafenib -- metabolism
No physical items for this record
Publication Type: Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.